hexagon background pattern hexagon background pattern

AUTOINFLAMMATORY DISEASES

Polygenic Diseases

Still’s Disease Is an Autoinflammatory Disease Driven by an Excess of Proinflammatory Cytokines, Including IL-1β1-3

Still’s disease is often thought of as a continuum of disease and includes1,2:

  • Systemic juvenile idiopathic arthritis (SJIA), which presents in patients younger than 16 years old
  • Adult-onset Still’s disease (AOSD), which presents in patients 16 years and older

Individuals with Still’s disease typically may have a combination of spiking fevers, rash, and arthritis/arthralgia2,4

  • The systemic and arthritic symptoms of Still’s disease can be debilitating, result in an inability to perform daily activities, and can have an impact on overall quality of life4-8
  • Possible long-term consequences of SJIA include joint damage, mobility loss, and slowing of growth2,5,8,9
  • Patients with AOSD can be at risk of joint erosion and disability, swelling in the lymphatic system and vital organs, and renal damage4,6,7
Ask the Expert

Learn about diagnosing Still’s disease from a medical expert.

WATCH MORE

All medical experts featured are speakers for Novartis and have been compensated for their time.

Rare Still’s disease includes the following:

Predominant ethnic distribution2

All ethnicities

Worldwide incidence2

0.4 to 0.8 per 100,000 people

Typical age at onset2

1 to 5 years

Predominant ethnic distribution4

All ethnicities

Worldwide incidence4*

0.16 per 100,000 people

Typical age at onset4

16 to 35 years

*Incidence reported from a retrospective study, including 62 patients from western France.

*Incidence reported from a retrospective study, including 62 patients from western France.

Ask the Expert

Listen in as medical experts describe Still’s disease in their own words.

WATCH MORE

All medical experts featured are speakers for Novartis and have been compensated for their time.

Patterns of Still’s Disease

Still’s disease has a variable disease course that generally falls into 3 distinct patterns4,11-14

1 circular shaped arrow representing monocyclic patterns or single episode of flares

Monocyclic

(single episode)

2 arrows in a circular shape representing polycyclic patterns or repeated flares in less than 10% of patients

Polycyclic or INTERMITTENT

(repeated flares)

4 arrows in a circular shape representing constant illness in greater than 50% of patients

Persistent/CHRONIC

(constant illness)

Diagnosing SJIA

International League of Associations for Rheumatology (ILAR) classification criteria15,16

As the diagnosis is clinical in nature, the ILAR classification criteria can be used as a guide

Arthritis
affecting ≥1 joints for ≥6 weeks

With or preceded by

FEVER
for ≥2 weeks occurring daily for ≥3 days

Plus ≥1 of the following

  1. Evanescent (nonfixed) erythematous rash
  2. Generalized lymphadenopathy
  3. Hepatomegaly and/or splenomegaly
  4. Serositis

Exclusion Criteria for ILAR15

  • Psoriasis or a history of psoriasis in the patient or first-degree relative
  • Arthritis in male who is HLA-B27 positive aged >6 years
  • Ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory bowel disease, Reiter’s syndrome, or acute anterior uveitis, or a history of one of these disorders in a first-degree relative
  • The presence of IgM rheumatoid factor on at least 2 occasions at least 3 months apart

Details of Clinical Manifestations

  • Arthritis ranges from oligoarticular to polyarticular with the wrists, knees, and ankles as the most commonly affected joints2
  • Fevers spike ≥39 °C and return to ≤37 °C between peaks15
  • Rash is transient, salmon colored, macular or maculopapular, and is typically found on the trunk, neck, and proximal extremities2
  • Highly elevated inflammatory markers, such as ESR and CRP, are usually present in patients with SJIA2
  • Additional laboratory abnormalities in SJIA include leukocytosis, thrombocytosis, and elevated ferritin and D-dimer levels2

Diagnosing AOSD

Yamaguchi classification criteria—diagnosis requires ≥5 criteria, including ≥2 major criteria17

Major criteria
  • Fever ≥39 °C lasting for ≥1 week
  • Arthralgia for ≥2 weeks
  • Macular or maculopapular, nonpruritic salmon-pink-colored rash
  • Leukocytosis (≥10,000/microL), including 80% or more of granulocytes
Minor criteria
  • Sore throat
  • Lymphadenopathy and/or splenomegaly
  • Abnormal liver function tests
  • Negative tests for rheumatoid factor and antinuclear antibody
Exclusions
  • Infections
  • Malignancies
  • Rheumatic diseases

Details of Clinical Manifestations4

  • Triad of symptoms that include high-spiking fevers, a characteristic rash, and arthritis/arthralgias
  • Rash is evanescent, salmon-pink, maculopapular eruption, and predominantly found on the proximal limbs and trunk, with rare involvement of the face and distal limbs
  • Often accompanied by fever, the rash can be mildly pruritic and confused with a drug allergy
  • Fevers are generally >39 °C and are transient, lasting typically under 4 hours and are most commonly daily or twice daily in pattern, with the highest temperatures seen in the late afternoon or early evening
  • Fever can spark the onset of other manifestations, including serositis, sore throat, myalgias, and arthralgias

Several common laboratory abnormalities in AOSD4

Elevated ESR and CRP

Leukocytosis

Thrombocytosis

Elevated ferritin levels, 5x upper limit of normal

hexagon icon Glycosylated ferritin is an especially important marker—in patients with AOSD, glycosylation of ferritin is often <20%4

Treatment Goals for Still’s Disease

Timely diagnosis is critical for patients with Still’s disease17,19

Treatment goals include16,20:

  • Control of active inflammation and symptoms
  • Prevent disease-related morbidities/end-organ damage
desktop hexagon background mobile hexagon background

Periodic Fever Syndromes (PFS) are also rare autoinflammatory diseases

AOSD=adult-onset Still’s disease; CRP=C-reactive protein; ESR=erythrocyte sedimentation rate; IgM=immunoglobulin M; IL-1β=interleukin 1 beta; SJIA=systemic juvenile idiopathic arthritis.
References: 1. Rossi-Semerano L, Koné-Paut I. Is Still’s disease an autoinflammatory syndrome? Int J Inflam. 2012;2012:480373. doi:10.1155/2012/480373 2. Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatr Clin North Am. 2018;65(4):691-709. doi:10.1016/j.pcl.2018.04.005 3. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34-42. doi:10.1038/ncprheum0681 4. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65(5):564-572. doi:10.1136/ard.2005.042143 5. Gurion R, Lehman TJA, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam. 2012;2012:271569. doi:10.1155/2012/271569 6. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24-36. doi:10.1016/j.jaut.2018.07.018 7. NORD (National Organization for Rare Disorders). Adult onset Still’s disease. Accessed March 16, 2020. https://rarediseases.org/rare-diseases/adult-onset-stills-disease/ 8. Sampalis JS, Esdaile JM, Medsger TA, et al. A controlled study of the long-term prognosis of adult Still’s disease. Am J Med. 1995;98(4):384-388. doi:10.1016/s0002-9343(99)80318-0 9. Batthish M, Feldman BM, Babyn PS, Tyrrell PN, Schneider R. Predictors of hip disease in the systemic arthritis subtype of juvenile idiopathic arthritis. J Rheumatol. 2011;38(5):954-958. doi:10.3899/jrheum.101146 10. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595-1601. doi:10.1002/art.21774 11. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416-426. doi:10.1038/nrrheum.2011.68 12. De Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. In: Petty RE, ed. Textbook Pediatric Rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2016:205-216.e7 13. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91-99. doi:10.1097/MD.0000000000000021 14. Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35(7):1683-1689. doi:10.1007/s10067-016-3308-8 15. Petty RE, Southwood TR, Manners P, et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. 16. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013;65(10):1551-1563. doi:10.1002/acr.22087 17. Kadavath S, Efthimiou P. Adult-onset Still’s disease—pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47(1):6-14. doi:10.3109/07853890.2014.971052 18. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424-430. 19. Hinze CH, Holzinger D, Lainka E, et al; PRO-KIND SJIA project collaborators. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. 2018;16(1):7. doi:10.1186/s12969-018-0224-2 20. Efthimiou P, Yadlapati S. Adult-onset Still’s disease. In: Efthimiou P, ed. Auto-Inflammatory Syndromes: Pathophysiology, Diagnosis, and Management. Springer; 2019:261-276.